Table 1.
Baseline recipient and medication characteristics of the pediatric transplant cohort, overall and by individual organ transplant groups
| Characteristics | Kidney | Heart | Liver | Lung | Multiple | Overall |
|---|---|---|---|---|---|---|
| Organ, n (%) | 145 (32.1) | 128 (28.4) | 147 (32.6) | 22 (4.9) | 9 (2) | 451 |
| Median age at transplantation (years), (IQR) | 13.3 | 3.7 | 2.9 | 12.7 | 1.5 | 8.3 |
| (8.3–15.6) | (0.5–13.2) | (0.8–10.3) | (10.5–15.2) | (1.2–3.0) | (1.3–14.1) | |
| Boys, n (%) | 90 (62.1) | 68 (53.1) | 82 (55.8) | 12 (54.5) | 7 (77.8) | 259 (57.4) |
| Median BMI at transplantation, Z scores (IQR) | 0.1 | −0.9 | 0.02 | −1.4 | −0.7 | −0.1 |
| (−0.4 to 1.2) | (−2 to 0.3) | (−0.9 to 0.8) | (−2.3 to − 0.1) | (−1.5 to 3.3) | (−1.2 to 0.9) | |
| Induction therapy, n (%) | 145 (100) | 128 (100) | 38 (25.8) | 9 (40.9) | 9 (100) | 329 (72.9) |
| Polyclonal antibodiesa | 47 (32.4) | 120 (93.7) | 23 (60.5) | <5 | 8 (88.9) | 199 (60.5) |
| IL-2 receptor antibodiesb | 98 (67.6) | 8 (6.2) | 15 (39.5) | 8 (88.9) | <5 | 130 (39.5) |
| Prednisone, n (%) | 145 (100) | 128 (100) | 145 (98.6) | 22 (100) | 9 (100) | 449 (99.5) |
| MMFc, n (%) | 143 (98.6) | 112 (87.5) | 20 (13.6) | 6 (27.3) | <5 | 282 (62.5) |
| CNI, n (%) | 144 (99.3) | 126 (98.4) | 147 (100) | 22 (100) | 9 (100) | 448 (99.3) |
| Tacrolimus | 143 (99.3) | 109 (86.5) | 145 (98.6) | <5 | 9 (100) | 410 (91.5) |
| Cyclosporine | <5 | 17 (13.5) | <5 | 18 (81.8) | 0 (0) | 38 (8.5) |
| Magnesium supplements, n (%) | 120 (82.7) | 66 (51.6) | 127 (86.4) | 21 (95.4) | 8 (88.9) | 342 (75.8) |
| Potassium supplements, n (%) | 60 (41.4) | 100 (78.1) | 86 (58.5) | 15 (68.2) | 7 (77.8) | 268 (59.4) |
| Proton pump inhibitors, n (%) | 27 (18.6) | 28 (21.9) | 98 (66.7) | 5 (22.7) | 6 (66.7) | 164 (36.4) |
| Median tacrolimus levels at Day 15 (ng/mL) (IQR) | 10.1 | 10.3 | 11.9 | 11.8 | 16.5 | 10.8 |
| (8.4–11.5) | (8.1–12.4) | (10.4–13.8) | (8.9–14.2) | (16.1–19) | (9.0–12.6) | |
| Median cyclosporine levels at Day 15 (ng/mL) (IQR) | 62 | 223 | 203 | 304.5 | 235.5 | |
| (151–268) | (96–203) | (229–323.5) | (151–309) |
Cell sizes <5 were collapsed due to privacy issues; medications data are presented for the first 15 days posttransplant.
a
Includes thymoglobulin; bincludes basiliximab and daclizumab; cMMF, mycophenolate mofetil.